U.S. Stock Market News | Weight-loss drug Zepbound expected to be approved in Japan next year, Eli Lilly up more than 1%

智通财经
2024.10.11 15:01

周五，礼来股价震荡上行，截至发稿，上涨 1.18%，报 921.435 美元。消息面上，礼来公司首席执行官周五表示，减肥药 Zepbound 有望明年在日本获批。

智通财经 APP 获悉，周五，礼来 (LLY.US) 股价震荡上行，截至发稿，上涨 1.18%，报 921.435 美元。消息面上，礼来公司首席执行官周五表示，减肥药 Zepbound 有望明年在日本获批。

Source: 智通财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.